GT Biopharma, Inc. (GTBP)

GT Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Depreciation & Amortization	0	0	0	0	0	0
Share-Based Compensation	1.48	2.2	7.65	33.93	0.27	5.31
Other Operating Activities	-1.95	-3.46	-1.98	8.48	20.77	29.68
Operating Cash Flow	-10.11	-8.85	-15.22	-15.61	-7.26	-3.66
Capital Expenditures	0	0	0	0	0	0.2
Change in Investments	10.01	-2.01	12.15	-23.04	0	0
Investing Cash Flow	10.01	-2.01	12.15	-23.04	0	0.2
Share Issuance / Repurchase	0	6.27	0	41.11	0	0
Debt Issued / Paid	0	0	0	1.21	12.53	3.43
Other Financing Activities	-	-	-0.22	-	-	-
Financing Cash Flow	0	6.27	-0.22	42.32	12.53	3.43
Net Cash Flow	-0.1	-4.59	-3.3	3.67	5.27	-0.03
Free Cash Flow	-10.11	-8.85	-15.22	-15.61	-7.26	-3.46
Free Cash Flow Per Share	-7.32	-6.57	-14.32	-16.63	-49.68	-30.66

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).